CLINICAL_TRIALS ClinicalTrials.gov record update

Effect of Natalizumab (Tysabri®) on Remyelination in Patients With Relapsing-remitting Multiple Sclerosis. A Follow-up Voxel-wise Magnetization Transfer Imaging Study.

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT00937677
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:35:07.890816+00:00
Published At: 2011-09-07T00:00:00+00:00
Record Updated At: 2011-09-07
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Multiple Sclerosis"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2011-09-07"
protocolSection.identificationModule.nctId: "NCT00937677"
protocolSection.identificationModule.officialTitle: "Effect of Natalizumab (Tysabri\u00ae) on Remyelination in Patients With Relapsing-remitting Multiple Sclerosis. A Follow-up Voxel-wise Magnetization Transfer Imaging Study."
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: []
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.